Launch of new Pompe treatment ‘exciting,’ Amicus chairman says
Bringing a third medication for late-onset Pompe disease (LOPD) to the treatment table is a personal triumph for Amicus Therapeutics executive chairman John Crowley. Pursuit of this new treatment for LOPD, while working to find a hoped-for cure, began just more than 25 years ago when Crowley’s children…